Biocryst Pharma Posts Profit In Q1; Sees Profit In FY25, Lifts ORLADEYO Revenue View; Stock Climbs

BioCryst Pharmaceuticals

12.29 CHF -10.75%

• Charts
• News
• Analysen

Kaufen Verkaufen

(RTTNews) - Biocryst Pharmaceuticals Inc. (BCRX), while reporting a profit in its first quarter compared to prior year's loss, on Monday said it expects to be profitable for full year 2025, a year ahead of schedule. The company also lifted ORLADEYO revenue guidance.

In pre-market activity on the Nasdaq, Biocryst shares were gaining around 18.7 percent to trade at $10.60.

The company now expects to deliver net income for full year 2025, while previously it was expected for full year 2026.

Global net ORLADEYO revenue is now projected to be between $580 million and $600 million, higher than previously expected $535 million to $550 million.

Operating expenses is now expected to be $440 million to $450 million, higher than previous view of $425 million to $435 million.

The company now expects to deliver positive cash flows in 2025, ahead of its previous expectation for fiscal 2026.

In the first quarter, net income was $32 thousand or $0.00 per share, compared to a net loss of $35.38 million or $0.17 per share for the first quarter of 2024.

The Wall Street analysts on average expected the company to report earnings of $5.80 per share on sales of $10.44 billion. Analysts' estimates typically exclude special items.

For the three months, total revenues were $145.53 million, significantly higher than $92.8 million a year ago.

The increase was primarily due to $134.2 million in ORLADEYO net revenue in the first quarter of 2025, compared to $88.9 million last year.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.